(+)-SJ000557733 (SJ733)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria, Falciparum
Conditions
Malaria, Falciparum, Malaria, Vivax
Trial Timeline
Apr 14, 2021 → Apr 15, 2022
NCT ID
NCT04709692About (+)-SJ000557733 (SJ733)
(+)-SJ000557733 (SJ733) is a phase 2 stage product being developed by Eisai for Malaria, Falciparum. The current trial status is completed. This product is registered under clinical trial identifier NCT04709692. Target conditions include Malaria, Falciparum, Malaria, Vivax.
What happened to similar drugs?
11 of 19 similar drugs in Malaria, Falciparum were approved
Approved (11) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04709692 | Phase 2 | Completed |
Competing Products
20 competing products in Malaria, Falciparum